Zephyr AI, a leader in precision medicine using AI to accelerate drug development, appointed Lisa Eli, PhD, as Chief Scientific Officer on April 21, 2026.
Dr. Eli has over 20 years of experience in translational medicine and precision oncology, leading biomarker-driven clinical development across Phase 1-3 trials.
She will accelerate AI-powered, biomarker-driven diagnostics and clinical development of targeted therapies at Zephyr AI.
The announcement was made via Business Wire from McLean, Virginia.